Although five-year survival rates for childhood acute lymphoblastic leukemia (ALL) are now over 80% in most industrialized countries 1 , not all children have benefited equally from this progress 2 . Ethnic differences in survival after childhood ALL have been reported in many clinical studies 3-11 , with poorer survival observed among African Americans or those with Hispanic ethnicity when compared with European Americans or Asians 3-5 . The causes of ethnic differences remain uncertain, although both genetic and non-genetic factors are likely important 4,12 . Interrogating genome-wide germline SNP genotypes in an unselected large cohort of children with ALL, we observed that the component of genomic variation that co-segregated with Native American ancestry was associated with risk of relapse (P = 0.0029) even after adjusting for known prognostic factors (P = 0.017). Ancestry-related differences in relapse risk were abrogated by the addition of a single extra phase of chemotherapy, indicating that modifications to therapy can mitigate the ancestry-related risk of relapse.
l e t t e r s remained prognostic (P = 0.017 when Native American ancestry was treated as a continuous variable; Table 3 ). To dichotomize Native American ancestry in a manner similar to the dichotomization used for other ALL prognostic features, such as leukocyte count, we divided patients into those with low (<10%) versus high (≥10%) Native American ancestry (see Supplementary Fig. 1 and Supplementary Note for details), and Native American ancestry remained associated with relapse (P = 3.6 × 10 −4 ; Supplementary Table 2) in the context of other dichotomized prognostic features. The same multivariate analysis that included self-declared Hispanic ethnicity instead of Native American ancestry also showed Hispanic ethnicity to be associated with relapse risk (P = 3.4 × 10 −3 ; Supplementary Table 2) . Unfavorable clinical features were not associated with Native American genetic ancestry ( Table 1 ). An important clinical indicator of relapse risk in ALL is the early response to therapy, determined by the level of MRD at the end of remission induction therapy. Even within the group of patients with negative MRD status, higher Native American genetic ancestry was linked to a higher risk of relapse (P = 0.08 when Native American ancestry was treated as a continuous variable, P = 0.006 when Native American ancestry was treated as a dichotomous trait (≥10% or <10% ancestry), n = 1,834; Supplementary Fig. 2 ). This is of clinical relevance, in that identifying a subgroup of patients who may need more intensive therapy despite negative MRD (indicating good response to initial therapy) would provide additional prognostic information.
Notably, the prognostic impact of Native American ancestry varied dependent upon specific treatment regimens. In the Children's Oncology Group (COG) P9904/P9905 study, patients were either randomized or non-randomly assigned to receive or not receive a delayed intensification phase (that is, an 8-week multi-agent treatment; Supplementary Table 3 ). Higher Native American ancestry was associated with higher relapse risk in children who did not receive delayed intensification (P = 0.015, n = 938; Fig. 2d ) but not in those who did receive this phase of therapy (P = 0.73, n = 667; Fig. 2e ). Similar results were observed when Native American ancestry was dichotomized as a prognostic feature (≥10% or <10% ancestry): P = 0.0016 for those who did not receive the delayed intensification and P = 0.51 for those who received the delayed intensification.
Delayed intensification consisted of 8 weeks of chemotherapy involving seven widely used anticancer drugs: dexamethasone, vincristine, daunorubicin, asparaginase, thioguanine, cyclophosphamide and cytarabine. For patients at lower risk of relapse, there has been some controversy as to whether the increased intensity of this phase of therapy (and its attendant slightly increased risk of complications such as infection 15 ) is worth the benefit of lower relapse rates, which have been observed in most but not all settings [16] [17] [18] . Delayed intensification is relatively well tolerated; it has been associated with an extra 5 days of hospitalization for its attendant toxicity (out of a total of ~134 weeks of ALL therapy) 19 . Thus, the benefits of delayed intensification are likely to outweigh the costs among the subset of patients with ≥10% Native American ancestry, exemplifying the importance and possibility of individualizing ALL therapy on the basis of genetic variation. Additional insights will be gained from clinical trials to examine the therapeutic efficacy of various phases of therapy (delayed intensification and other phases), set in the context of other therapeutic regimens, in patients with a high versus low percentage of Native American ancestry.
To further illustrate the evidence for the association between ancestry and relapse, we examined local Native American ancestry across the genome for association with ALL relapse using admixture mapping 20 . Of 3,682 genomic segments with unique Native American ancestry status, local Native American ancestry at several loci was associated with relapse, with a locus at 2p25. 3 (rs17039396) showing the strongest association between local Native American ancestry and relapse (nominal P = 3.2 × 10 −7 ; the genome-wide threshold for significance was P = 1.4 × 10 −5 based on 3,682 independent loci tested; Supplementary Note and Supplementary Fig. 3 ). Likewise, admixture mapping using a previously published admixture map for Hispanics 13 from the United States also identified 2p25.3 as having genome-wide significance for association with relapse (nominal P = 1.1 × 10 −6 ; the genome-wide threshold for significance was P = 2.4 × 10 −5 ; Supplementary Fig. 3 ). 
l e t t e r s
To explore the mechanisms by which ancestry may affect ALL relapse risk, we also examined which individual SNP genotypes were significantly associated with relapse risk, with the phenotype defined as 'any' relapse (hematologic plus extramedullary) as well as more narrowly defined as the most common (and deadly) form of relapse, hematologic relapse. A SNP in PDE4B (rs6683977) was the highest ranked SNP associated with hematologic relapse (P = 2.2 × 10 −6 ) and was also associated with any relapse risk ( Supplementary Figs. 4 and 5) , and admixture mapping indicated that local Native American ancestry at 1p32.2-31.3 that encompassed SNPs in PDE4B (including rs6683977) showed a significant association signal (P = 3.2 × 10 −6 for that locus; the P value threshold for genome-wide significance was P = 1.4 × 10 −5 ; Supplementary Note and Supplementary Fig. 3) . Notably, primary ALL cells expressing higher levels of PDE4B were also more resistant to prednisolone (Supplementary Fig. 6 ), indicating that PDE4B might play a role in glucocorticoid response in ALL.
The association we observed between genomically defined Native American ancestry and relapse is consistent with higher ALL relapse risk among Hispanics [3] [4] [5] . The high risk of relapse associated with Native American ancestry was not explained by an association of Native American ancestry with known ALL relapse risk factors (Tables 1 and 3) . The association was similar when we confined the analysis to self-reported whites (Fig. 2c) , which is consistent with a genetic (rather than cultural or environmental) basis for the elevated risk of leukemia relapse in Hispanics. However, we cannot exclude the possibility that environmental, sociocultural or dietary differences that are associated with Native American ancestry also or even primarily influence relapse risk.
Although current risk classification schemes identify children with more aggressive ALL, a substantial portion of patients are not cured with contemporary chemotherapy, and a substantial portion of patients who ultimately relapse are considered at low risk for relapse l e t t e r s or do not exhibit MRD 21, 22 . For these reasons, it was interesting that Native American ancestry identified a group of patients who benefited from the use of an extra phase of chemotherapy (delayed intensification; Fig. 2d,e) , and there was a trend for prognostic importance of Native American ancestry even within the group exhibiting negative MRD (Supplementary Fig. 2 ), indicating that germline genomic variation may add prognostic value to current ALL risk stratification schema.
There are likely many mechanisms by which ancestry-related germline polymorphisms could affect drug response: our data illustrate that ancestry-related genomic variation could affect the probability of cure in part by affecting drug resistance. However, all such outcomes (and therefore the identification of genetic prognostic features) are also dependent upon therapy. Our data illustrate that giving additional chemotherapy can overcome the negative prognostic impact conferred by a set of ancestry-related polymorphisms and thereby mitigate ethnic disparities in the outcome of childhood ALL.
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